Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554150 | 0.98 | — | — | |
| SCHEMBL7069886 | 0.86 | CTNNB1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL9650562 | 0.81 | ALDH1A1 (0.37) | CA2TSHRALDH1A1ABCB11CYP3A4 | |
| SCHEMBL7043209 | 0.80 | CA2 (0.38) | CA2TSHRALDH1A1AKT1NAMPT | |
| SCHEMBL3542040 | 0.78 | ALDH1A1 (0.43) | CA2TSHRALDH1A1NAMPTABCB11 | |
| SCHEMBL18244613 | 0.78 | ALDH1A1 (0.43) | CA2TSHRALDH1A1NAMPTABCB11 | |
| SCHEMBL2603682 | 0.78 | CES2 (0.50) | CA2TSHRALDH1A1NAMPTABCB11 | |
| SCHEMBL10019282 | 0.78 | ALDH1A1 (0.43) | CA2TSHRALDH1A1NAMPTABCB11 | |
| SCHEMBL102373 | 0.78 | ALDH1A1 (0.43) | CA2TSHRALDH1A1NAMPTABCB11 | |
| SCHEMBL11421530 | 0.78 | ALDH1A1 (0.50) | TSHRALDH1A1EPHX2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1060161-B1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-06-11 | — | — | EP | disclosed |
| US-6277876-B1 | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2001-08-21 | — | — | US | disclosed |
| EP-1060161-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999044989-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | CA2 2568/4885TSHR 3901/4885ALDH1A1 123/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CA2 2212/4885TSHR 3622/4885ALDH1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.